We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or...
Putting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of 'Precision Medicine in Cancer Care' PR Newswire DARMSTADT, Germany, September 26, 2014 DARMSTADT...
Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time PR Newswire DARMSTADT, Germany, September 19, 2014 DARMSTADT, Germany, September 19, 2014 /PRNewswire/ -- The first grants...
Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age PR Newswire DARMSTADT, Germany, September 3, 2014 DARMSTADT, Germany, September...
Merck Serono Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide PR Newswire NANTONG, China, August 27, 2014 NANTONG, China, August 27...
Merck Serono Announces FDA Clearance for Auxogyn's Early Embryo Viability Assessment (Eeva®) System PR Newswire DARMSTADT, Germany, June 10, 2014 DARMSTADT, Germany, June 10, 2014 /PRNewswire/...
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers PR Newswire ROCKLAND, Massachusetts, May 29, 2014 ROCKLAND...
Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal PR Newswire DARMSTADT, Germany and PARIS, April 17, 2014 DARMSTADT, Germany and PARIS, April...
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors PR Newswire DARMSTADT, Germany, December 23, 2013 DARMSTADT, Germany...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.55 | -1.6335682255 | 156.1 | 158 | 149.44999 | 9149 | 153.21627515 | DE |
4 | -2.14999 | -1.38085429549 | 155.69999 | 168.1 | 149.44999 | 8433 | 157.54051762 | DE |
12 | -12.5 | -7.52785305631 | 166.05 | 176.9 | 149.44999 | 6604 | 161.77990872 | DE |
26 | 0.65 | 0.425114453891 | 152.9 | 176.9 | 147.4 | 7156 | 161.72730961 | DE |
52 | 6.10001 | 4.13700265426 | 147.44999 | 176.9 | 134.35 | 9588 | 153.59773442 | DE |
156 | -60.55 | -28.2811770201 | 214.1 | 231.5 | 134.35 | 197165 | 177.3106639 | DE |
260 | 45.05 | 41.5207373272 | 108.5 | 231.5 | 76.22 | 305570 | 146.16567934 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions